$JUV Recent favorable developments! Eli Lilly's $650 million collaboration is finalized + Tether doubles its bid to acquire Juventus (valuation exceeds €2 billion), core pipeline JUV-161 is progressing smoothly in clinical trials, with dual support from ecology and capital, strong momentum for future increases, bullish without hesitation! $JUV

JUV

0.811

-9.88%